Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7919499 | ALKERMES | Naltrexone long acting formulations and methods of use |
Oct, 2029
(6 years from now) |
Drugs and Companies using NALTREXONE ingredient
Market Authorisation Date: 13 April, 2006
Treatment: Prevention of relapse to opioid dependence, following opioid detoxification; Treatment of alcohol dependence
Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR
17
United States
2
Korea, Republic of
2
China
2
Japan
2
European Union
1
New Zealand
1
Russia
1
South Africa
1
Canada
1
Australia
1
United Kingdom
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic